Optimising TREATment for Severe Gram-Negative Bacterial Infections

计划入组 600 人 · 首次发布于 2025 年 6 月 4 日

Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections

计划入组 810 人 · 首次发布于 2023 年 7 月 12 日

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

首次发布于 2018 年 12 月 19 日

RC-01 (intravenous, Gram-negative bacterial infections), Recida Therapeutics/MicuRx Pharmaceuticals

antibiotics (Gram-positive bacterial infections)

Grepafloxacin

C₁₉H₂₂FN₃O₃

Infant Bacterial Therapeutics AB

Sweden

Spero Therapeutics

United States

Armata Pharmaceuticals

United States

Flightpath Biosciences Licenses Microbiome-Sparing Antibiotic Lolamicin for Gram-Negative Bacterial Infections

Centauri Therapeutics Advances Novel Immunotherapy Against Gram-negative Bacterial Infections to Clinical Stage

Shionogi's Cefiderocol Receives Priority Review in China for Gram-Negative Bacterial Infections